Potential use of tumour marker CA 15-3 in the staging and prognosis of patients with breast cancer.
J R Coll Surg Edinb
; 36(4): 219-21, 1991 Aug.
Article
in En
| MEDLINE
| ID: mdl-1941734
ABSTRACT
The tumour marker CA 15-3 has been assayed in 130 patients with breast cancer and correlated with stage of their disease at presentation. The median value of CA 15-3 (43 kU/l) in 26 patients with stage IV disease was significantly higher than the median for 97 patients classified as stage I or II (17 kU/l). Values were elevated in 18 of 21 (86%) patients with bone metastases at presentation. For the 41 patients with stage I or II disease presenting with levels of CA 15-3 of greater than 20 kU/l, the disease-free interval and survival were significantly less than for 56 patients presenting with levels of less than 20 kU/l. CA 15-3 provides additional information to conventional staging tests for patients presenting with breast cancer and may also have a role as a prognostic indicator. This may be particularly useful in the selection of patients for neoadjuvant therapy.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Bone Neoplasms
/
Breast Neoplasms
/
Antigens, Tumor-Associated, Carbohydrate
/
Biomarkers, Tumor
Type of study:
Diagnostic_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Language:
En
Journal:
J R Coll Surg Edinb
Year:
1991
Document type:
Article
Affiliation country: